Jose Meca-Lallana

14PUBLICATIONS
111CO-AUTHORS
PharmacogenomicsNeurology and neuromuscular diseasesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 15, 2026
Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

|Jun 12, 2026
Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

|May 15, 2026
Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

|Apr 01, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Andrea Surcinelli, Tomas Kalincik, Izanne Roos

|Mar 05, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Pakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt

|Aug 05, 2025
Neurologists' Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants.

Enric Monreal, Rocío Gómez-Ballesteros, Virginia Meca-Lallana

Pageof 3

Frequent Collaborators

4 joint publications

Jorge Millán-Pascual

4 joint publications

Lucienne Costa-Frossard

3 joint publications

Gary Álvarez Bravo

3 joint publications

Jorge Maurino